Protein Processing Section, Structural Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Mol Cell Biol. 2020 Aug 28;40(18). doi: 10.1128/MCB.00122-20.
hRpn13/ADRM1 links substrate recruitment with deubiquitination at the proteasome through its proteasome- and ubiquitin-binding Pru domain and DEUBAD domain, which binds and activates deubiquitinating enzyme (DUB) UCHL5/Uch37. Here, we edit the HCT116 colorectal cancer cell line to delete part of the hRpn13 Pru, producing cells that express truncated hRpn13 (trRpn13), which is competent for UCHL5 binding but defective for proteasome interaction. cells demonstrate reduced levels of proteasome-bound ubiquitinated proteins, indicating that the loss of hRpn13 function at proteasomes cannot be fully compensated for by the two other dedicated substrate receptors (hRpn1 and hRpn10). Previous studies indicated that the loss of full-length hRpn13 causes a corresponding reduction of UCHL5. We find UCHL5 levels unaltered in cells, but hRpn11 is elevated in and cells, perhaps from cell stress. Despite the ∼90 DUBs in human cells, including two others in addition to UCHL5 at the proteasome, we found deletion of UCHL5 from HCT116 cells to cause increased levels of ubiquitinated proteins in whole-cell extract and at proteasomes, suggesting that UCHL5 activity cannot be fully assumed by other DUBs. We also report anticancer molecule RA190, which binds covalently to hRpn13 and UCHL5, to require hRpn13 Pru and not UCHL5 for cytotoxicity.
hRpn13/ADRM1 通过其与蛋白酶体和泛素结合的 Pru 结构域和 DEUBAD 结构域将底物募集与蛋白酶体处的去泛素化连接起来,该结构域与并激活去泛素化酶 (DUB)UCHL5/Uch37。在这里,我们编辑了 HCT116 结直肠癌细胞系以删除 hRpn13 Pru 的一部分,产生表达截断 hRpn13(trRpn13)的细胞,该细胞能够与 UCHL5 结合,但不能与蛋白酶体相互作用。细胞表现出结合蛋白酶体的泛素化蛋白水平降低,表明在蛋白酶体处 hRpn13 功能的丧失不能完全由另外两个专用底物受体 (hRpn1 和 hRpn10) 来弥补。先前的研究表明全长 hRpn13 的缺失会导致 UCHL5 的相应减少。我们发现 细胞中的 UCHL5 水平没有改变,但 hRpn11 在 和 细胞中升高,可能是细胞应激所致。尽管人类细胞中有大约 90 种 DUB,包括蛋白酶体上除 UCHL5 之外的另外两种,我们发现从 HCT116 细胞中删除 UCHL5 会导致整个细胞提取物和蛋白酶体中泛素化蛋白水平升高,这表明 UCHL5 的活性不能完全由其他 DUB 承担。我们还报告了抗癌分子 RA190,它与 hRpn13 和 UCHL5 共价结合,需要 hRpn13 Pru 而不是 UCHL5 来发挥细胞毒性。